Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Targretin bexarotene capsules: Phase II data; Marketed to treat refractory cutaneous T cell lymphoma (CTCL)

LGND presented interim data from 3 of 4 dosage groups in its 37-patient European Phase II trial

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE